Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883536 | 0.82 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBPDK2 | |
| SCHEMBL2883532 | 0.82 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBPDK2 | |
| SCHEMBL21464535 | 0.82 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBPDK2 | |
| Hydrochloric Acid SCHEMBL3427002 | 0.81 | L3MBTL3 (0.49) | L3MBTL3KDM1AMAOAMAOBPDK2 | |
| Hydrochloric Acid SCHEMBL3404368 | 0.81 | L3MBTL3 (0.49) | L3MBTL3KDM1AMAOAMAOBPDK2 | |
| SCHEMBL12522299 | 0.80 | CHRNB2 (0.48) | L3MBTL3PDK2 | |
| SCHEMBL16570183 | 0.79 | L3MBTL3 (0.40) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| SCHEMBL4239148 | 0.79 | L3MBTL3 (0.40) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| SCHEMBL24127448 | 0.78 | MAPT (0.39) | L3MBTL3PDK2 | |
| SCHEMBL22647515 | 0.78 | L3MBTL3 (0.37) | L3MBTL3KDM1AMAOAMAOBPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | claimed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | claimed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3877390-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| EP-3349580-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| CN-105348266-B | 3 chlorine N [3 (the base amino of the pyrimidine 2) phenyl] propionamides or its salt of substitution | 阿斯利康(瑞典)有限公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-105198862-B | The substituted amines of N (nitrobenzophenone of 4 fluorine, 2 methoxyl group 5) pyrimidine 2 and its salt | 阿斯利康(瑞典)有限公司 | 2018-01-23 | — | — | CN | disclosed |
| CN-105175396-B | 4 methoxyl group N of substitution3The diamine compound of (base of pyrimidine 2) benzene 1,3 and its salt | 阿斯利康(瑞典)有限公司 | 2018-01-16 | — | — | CN | disclosed |
| CN-105254616-B | The substituted amines of N (nitrobenzophenone of 2 methoxyl group 5) pyrimidine 2 and its salt | 阿斯利康(瑞典)有限公司 | 2017-10-17 | — | — | CN | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1906167-A | Novel pyridine derivative and pyrimidine derivative (2) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1620437-A1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | L3MBTL3 4875/4885KDM1A 4208/4885MAOA 844/4885 |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | L3MBTL3 3619/4885KDM1A 479/4885MAOA 862/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | L3MBTL3 1402/4885KDM1A 4221/4885MAOA 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.